Jan H von der Thusen
Overview
Explore the profile of Jan H von der Thusen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
123
Citations
1866
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
31.
van Uden D, Koudstaal T, van Hulst J, van den Bosch T, Vink M, Bergen I, et al.
Front Immunol
. 2022 May;
13:861450.
PMID: 35572511
Introduction: Previous studies have shown an increase of T cells and chemokines in vascular lesions of patients with chronic thromboembolic pulmonary hypertension (CTEPH). However, detailed characterization of these T cells...
32.
Verhoeven J, Hesselink D, Peeters A, de Jonge E, von der Thusen J, van Schaik R, et al.
Transpl Int
. 2022 Apr;
35:10122.
PMID: 35387397
In heart transplant recipients, donor-derived cell-free DNA (ddcfDNA) is a potential biomarker for acute rejection (AR), in that increased values may indicate rejection. For the assessment of ddcfDNA as new...
33.
Butter R, Hondelink L, van Elswijk L, Blaauwgeers J, Bloemena E, Britstra R, et al.
Lung Cancer
. 2022 Mar;
166:143-149.
PMID: 35279453
Objectives: Programmed death-ligand 1 (PD-L1) is the only approved predictive biomarker for immunotherapy in non-small cell lung cancer (NSCLC). However, predictive PD-L1 immunohistochemistry is subject to interobserver variability. We hypothesized...
34.
van Kooten J, Belderbos R, von der Thusen J, Aarts M, Verhoef C, Burgers J, et al.
Thorax
. 2022 Feb;
77(12):1260-1267.
PMID: 35149582
Introduction: Malignant mesothelioma (MM) is an aggressive cancer that primarily arises from the pleura (MPM) or peritoneum (MPeM), mostly due to asbestos exposure. This study reviewed the Dutch population-based incidence,...
35.
Sklepkiewicz P, Dymek B, Mlacki M, Koralewski R, Mazur M, Nejman-Gryz P, et al.
Eur J Pharmacol
. 2022 Feb;
919:174792.
PMID: 35122869
Idiopathic pulmonary fibrosis (IPF) is a progressive and eventually fatal lung disease with a complex etiology. Approved drugs, nintedanib and pirfenidone, modify disease progression, but IPF remains incurable and there...
36.
Steendam C, Atmodimedjo P, de Jonge E, Paats M, van der Leest C, Oomen-de Hoop E, et al.
JCO Precis Oncol
. 2022 Feb;
3:1-9.
PMID: 35100738
Purpose: To compare the results of plasma cell-free DNA (cfDNA) droplet digital PCR (ddPCR) and next-generation sequencing (NGS) on detection of epidermal growth factor receptor () primary activating mutations and...
37.
Verhagen J, Burger J, Bekkers J, den Dekker A, von der Thusen J, Zajec M, et al.
Int J Mol Sci
. 2022 Jan;
23(1).
PMID: 35008861
Thoracic aortic aneurysm is a potentially life-threatening disease with a strong genetic contribution. Despite identification of multiple genes involved in aneurysm formation, little is known about the specific underlying mechanisms...
38.
Hondelink L, Jebbink M, von der Thusen J, Cohen D, Dubbink H, Paats M, et al.
JTO Clin Res Rep
. 2021 Dec;
2(12):100252.
PMID: 34849493
Introduction: With the approval of first-line osimertinib treatment in stage IV EGFR-mutated NSCLC, detection of resistance mechanisms will become increasingly important-and complex. Clear guidelines for analyses of these resistance mechanisms...
39.
Hermelijn S, Mackenbach M, van Horik C, Ciet P, Wolf J, von der Thusen J, et al.
J Pediatr Surg
. 2021 Nov;
57(8):1567-1572.
PMID: 34809963
Background: Risk for infection and potential malignant degeneration are the most common arguments for resecting asymptomatic Congenital Pulmonary Airway Malformations (CPAM). We aimed to investigate if CT- imaging characteristics can...
40.
Hondelink L, Huyuk M, Postmus P, Smit V, Blom S, von der Thusen J, et al.
Histopathology
. 2021 Nov;
80(4):635-647.
PMID: 34786761
Aims: Immunohistochemical programmed death-ligand 1 (PD-L1) staining to predict responsiveness to immunotherapy in patients with advanced non-small cell lung cancer (NSCLC) has several drawbacks: a robust gold standard is lacking,...